Evaluation of Liver Damage in Patients With Anorexia Nervosa by Blood Biomarker Analysis

Nantes University Hospital50 enrolled

Overview

The main goal of the BIocoLlection in Anorexia Nervosa-liver damage evaluation BILAN study the blood biomarkers associated with liver cytolysis.

Study of the association between blood biomarkers and the presence of hepatic cytolysis, defined by AST and/or ALT above normal.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Anorexia Nervosa

Interventions

Patients with Anorexia NervosaOTHER

Patients with Anorexia Nervosa hospitalized for malnutrition

Eligibility

Sex: ALLMin age: 15 YearsMax age: 99 Years

Medical Language ↔ Plain English

Inclusion Criteria : * Patient over 15 years old * Diagnosis of Restricted Eating Disorders including Anorexia Nervosa according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) * Admission to Nantes University Hospital. Exclusion Criteria : * Chronic active viral hepatitis * Hemochromatosis * Other genetic, autoimmune. * Treatment with a drug known to induce fatty liver disease (amiodarone, carbamazepine, tamoxifen, valproate, clozapine, anti-retrovirals) unless the dose has been stable for ≥ 3 months * Excessive alcohol consumption (≥ 30 grams per day in men, ≥ 20 grams per day in women) * Pregnant, parturient or breast-feeding women, persons deprived of liberty, adults under legal protection or unable to express their consent, persons not affiliated or not beneficiaries of a social security scheme, persons under guardianship or curators

Locations (1)

Nantes University Hospital

Nantes, Loire-Atlantique, France

RECRUITING

Outcomes

Primary Outcomes

Identification of new blood biomarkers and hepatic cytolysis

Identify changes in concentration of new blood biomarkers in patients suffering from hepatic cytolysis, defined by aspartate transaminases (AST) and/or alanine transaminases (ALT) above normal values, compared to those with normal enzyme levels.

Time frame: Two years

Central Contacts

Sarra SMATI-GRANGEON, PH

CONTACT

33 2 53 48 27 01 sarra.grangeon@chu-nantes.fr

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.